Trials / Completed
CompletedNCT04603586
Stereotactic Radiotherapy in Locally Advanced Pancreatic Cancer With Different Biological Effective Doses
A Prospective Phase Ⅱ Clinical Study of Stereotactic Radiotherapy Combined With Chemotherapy With Different Biological Effective Doses (<70gy vs. >70Gy) in Locally Advanced Pancreatic Cancer
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 119 (actual)
- Sponsor
- Changhai Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to compare the safety and efficacy of SBRT in LAPC with different biological effective dose (BED) (\<70Gy Vs.\>70Gy ) , to identify a dose range that could achieve better survival benefit and minimize the toxicity of radiotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | SBRT | SBRT: in 5-6 fractions with CyberKnife |
| DRUG | Chemotherapy | Gemcitabine 1000mg/m\^2 and nab-paclitaxel 125mg/m\^2, administered intravenously, on day 1 and 8 of a 21-day cycle for six cycles |
Timeline
- Start date
- 2020-11-10
- Primary completion
- 2025-08-15
- Completion
- 2025-08-15
- First posted
- 2020-10-27
- Last updated
- 2025-10-20
- Results posted
- 2025-10-20
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04603586. Inclusion in this directory is not an endorsement.